+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06195072

A Multicenter, Randomized, Double-Blind Study Comparing Investigational Drugs Amlitelimab and BI 1015550 to Placebo in Patients with Interstitial Lung Disease Secondary to Systemic Sclerosis

Led by Scleroderma Research Foundation, Inc. · Updated on 2026-08-18

400

Participants Needed

34

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of different investigational drugs compared to placebo in people with Interstitial Lung Disease caused by Systemic Sclerosis. The goal is to see how these treatments affect lung capacity over a one-year period. This phase 2b study is randomized, double-blind, and placebo-controlled, aiming to find better options for managing this lung condition associated with scleroderma. Participants will receive one of two investigational drugs or a matching placebo. One drug, Amlitelimab, is given as an injection under the skin by the study staff. The other drug, BI 1015550 Nerandomilast, is taken orally as tablets twice daily. The treatment lasts for 52 weeks, during which lung function and other health measures will be closely monitored. Throughout the study, participants will undergo tests including lung function tests measuring forced vital capacity FVC, imaging scans to assess lung fibrosis, and questionnaires about breathing difficulties. Researchers will track changes from the start of treatment through Week 52. Safety and efficacy data will be collected during this time, and participants health will be carefully observed until the study concludes.

CONDITIONS

Brief Title

Platform Clinical Study for Conquering Scleroderma

Research Team

G

Gabrielle Khedr

K

Kevin O'Shea

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here